Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
VHL
REST API REST API
Homo sapiens
VHL is differentially expressed in 185 experiments: 66 organism parts: thymus, esophagus, ... (64 more);, 99 disease states: normal, breast carcinoma, ... (97 more);, 60 cell types 139 cell lines 29 compound treatments and 63 other conditions.
Synonyms VHL1
Orthologs vhl (Danio rerio)   Vhl (Mus musculus)   VHL (Bos taurus)   VHL (Gallus gallus)   Vhl (Rattus norvegicus)   vhl (Xenopus laevis)   VHL_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term angiogenesis, neuron differentiation, cytosol, protein stabilization, endoplasmic reticulum, protein binding, regulation of transcription, DNA-dependent, cytoplasm, protein catabolic process, negative regulation of cell proliferation, protein ubiquitination, membrane, response to stress, anti-apoptosis, response to hypoxia, cell morphogenesis, transcription factor binding, VCB complex, nucleus, proteolysis, negative regulation of transcription from RNA polymerase II promoter, extracellular matrix organization, response to ethanol, positive regulation of transcription, DNA-dependent, mitochondrion, regulation of catecholamine metabolic process, blood vessel endothelial cell migration, positive regulation of cell differentiation
UniProt Accession A0PJF6, A4ZYX2, B4E1V7, P40337, E7EPH2
Gene-Disease Assocation PHEOCHROMOCYTOMA, ERYTHROCYTOSIS, FAMILIAL, 2; ECYT2, VON HIPPEL-LINDAU SYNDROME; VHL, RENAL CELL CARCINOMA, NONPAPILLARY; RCC
InterPro Term VHL_tumour_suppress_b/a_dom
Search EB-eye ENSG00000134086
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-MEXP-1006, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (26 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-19639, E-GEOD-20081
primary culture
2
E-GEOD-2450, E-GEOD-1657
PC-3MM2
1
E-MEXP-2172
MDA468
1
E-MTAB-62
CORL88
1
E-MTAB-37
Raji
1
E-MTAB-37
133 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-4219, ... (32 experiments)

Factor Value U/D Experiments
plasma cell
2
E-MEXP-2360, E-GEOD-6691
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
neutrophil
1
E-GEOD-12662
undifferentiated cell
1
E-GEOD-21668
germ cell
1
E-MTAB-25
kidney cell
1
E-MEXP-1216
54 more value(s).


Disease state

studied in E-GEOD-6872, E-GEOD-2466, E-GEOD-2549, E-GEOD-22148, E-GEOD-16363, ... (34 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-GEOD-96
normal
7
8
E-GEOD-13987, E-GEOD-9692, E-GEOD-6919, E-GEOD-12662, E-TABM-276, ... (15 experiments)
NDV
1
E-GEOD-18791
Non-decidualised
1
E-MTAB-680
93 more value(s).


Compound treatment

studied in E-GEOD-15205, E-GEOD-697, E-TABM-782, E-TABM-868, E-GEOD-5418, ... (15 experiments)

Factor Value U/D Experiments
mercaptopurine, methotrexate
1
E-GEOD-412
no estradiol
1
E-GEOD-20081
poly(I:C)
1
E-MEXP-1230
control - untreated
1
E-GEOD-7216
bacterial endotoxin
1
E-GEOD-3284
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
23 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-19293 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

Developmental stage
studied in E-GEOD-19743

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-20847, E-MTAB-108, E-GEOD-6431, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-TABM-868, E-TABM-601, E-GEOD-1153, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-12773, E-GEOD-20540, E-GEOD-20504, ... (9 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-15, ... (29 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-15811

RNAi
studied in E-MEXP-101

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-23984

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271

Tumor size
studied in E-GEOD-6532

Processing time: 0.375 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM